Mylan, Pfizer Say EpiPen Antitrust Suits Don't Need MDL
However, if the panel finds MDL is fitting, Mylan and Pfizer said it should be done in Kansas where the bulk of the litigation is already taking place, not New Jersey as the plaintiffs bringing the consolidation motion requested. Eight potential class...
To view the full article, register now.
Try Law360 FREE for seven days
Already a subscriber? Click here to login